Email this article Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata
- Authors: Desheva Y.A.1,2, Smolonogina T.A.1, Doroshenko E.M.1, Rudenko L.G.1
-
Affiliations:
- Institute of Experimental Medicine
- St. Petersburg State University
- Issue: Vol 61, No 1 (2016)
- Pages: 16-20
- Section: ORIGINAL RESEARCH
- Submitted: 09.07.2020
- Accepted: 09.07.2020
- Published: 28.02.2016
- URL: https://virusjour.crie.ru/jour/article/view/298
- DOI: https://doi.org/10.18821/0507-4088-2016-61-1-16-20
- ID: 298
Cite item
Full Text
Abstract
This work is devoted to the research of the live attenuated influenza vaccine (LAIV) comprising two reassortant B/USSR/60/69-based vaccine influenza viruses Victoria and Yamagata. the intranasal immunization of the CBA mice with both victoria and yamagata strains induced 100% lung protection against the subsequent infection with the wild-type influenza B viruses of any antigen lineage. the quadrivalent LAIV (qLAIV) comprising both reassortant influenza B viruses Victoria and Yamagata were safe and areactogenic in adult volunteers. Following qLAIV administration the immune response was achieved to both Victoria and Yamagata lineages.
Keywords
About the authors
Yu. A. Desheva
Institute of Experimental Medicine; St. Petersburg State University
Author for correspondence.
Email: desheva@mail.ru
Yuliya Desheva, MD, PhD, DS
197376, St. Petersburg
199034, St. Petersburg
T. A. Smolonogina
Institute of Experimental Medicine
Email: fake@neicon.ru
197376, St. Petersburg Russian Federation
E. M. Doroshenko
Institute of Experimental Medicine
Email: fake@neicon.ru
197376, St. Petersburg Russian Federation
L. G. Rudenko
Institute of Experimental Medicine
Email: fake@neicon.ru
197376, St. Petersburg Russian Federation
References
- Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28 (Suppl. 4): D45–53.
- Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization PracticesUnited States, 2013–2014. MMWR Recomm. Rep. 2013; 62 (RR-07): 1–43.
- Toback S.L., Levin M.J., Block S.L., Belshe R.B., Ambrose C.S., Falloon J. Quadrivalent Ann Arbor strain live attenuated influenza vaccine. Expert Rev. Vaccines. 2012; 11(11): 1293–303.
- Alexandrova G.I., Maassab H.F., Kendal A.P., Medvedeva T.E., Egorov A.Y., Klimov A.I. et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine. 1990; 8: 61–4.
- Ларионова Н.В., Киселева И.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Малайзия/04/898 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2416639, 2009.
- Ларионова Н.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Флорида/04/181 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2422519, 2010.
- Ларионова Н.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Брисбен/08/83 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2422517, 2010.
- World Health Organization Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
- Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 2012; 8(1): 81–8.
- Романова Ю.Р., Александрова. Г.И. Интерференция и ее преодоление при репродукции двух штаммов вируса гриппа А в эксперименте. Вопросы вирусологии. 1993; 38(4): 149–52.
- Руденко, Л.Г., Рамирес А., Барро М., Гущина М.И., Арманда Р.Е., Ермаченко Т.А. и др. Прививочные свойства живой гриппозной рекомбинантной вакцины типов А и В при раздельном и совместном применении детям 3-14 лет. Вопросы вирусологии. 1991; 36(6): 472-4.
- Skowronski D.M., Hamelin M.E., Janjua N.Z., De Serres G., Gardy J.L., Rhéaume C. et al. Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. PLoS One. 2012; 7(6): e38929.
- Xu X., Lindstrom S.E., Shaw M.W., Smith C.B., Hall H.E., Mungall B.A. et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004; 103(1–2): 55–60.
- Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi. T. et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 2012; 31(7): 745–51.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).